Arca
Skip to content
Tools
Tools

Cardiomyopathy

Drug research and approvals for cardiomyopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 364 studies of cardiomyopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 33 drug trials for it since 2013, FDA has 9 approved and 16 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 364
  • Trials authorized in Canada: 33
  • FDA orphan approvals: 9
  • EU medicines: 4

Recruiting now

Newest posted first, of 364 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,261 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 200 whose ending is known, 45% met their primary endpoint, 6% missed it and 50% stopped early.

  • Ongoing42233%
  • Completed, result not reported41333%
  • Status unknown22618%
  • Met its primary endpoint907%
  • Stopped: other or unclear524%
  • Stopped: enrollment or feasibility222%
  • Stopped: sponsor or business decision131%
  • Missed its primary endpoint111%
  • Stopped: lack of efficacy5<1%
  • Stopped: funding5<1%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 33; search them all in Canada trials
Apr 1, 2026A phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220…ALXN2220 / Wainua, wainzuaAstraZeneca PharmaceuticalsOngoing
Mar 20, 2026A phase 1/2 multicenter, open-label, dose-escalation and dose-expansion trial to assess the safety, tolerability, pharmacodynamics, and preliminary efficacy of…AFTX-201Affinia TherapeuticsOngoing
Sep 12, 2025Cleopattra: effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTRCM)Coramitug (NNC6019-0001)Novo NordiskOngoing
Aug 26, 2025A phase 3, open-label, multicenter, extension study of acoramidis in patients with newly diagnosed variant transthyretin amyloid cardiomyopathy (actearly ole)Acoramidis (AG10)Eidos TherapeuticsOngoing
Jun 20, 2025A phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nucresiran in patients with transthyretinmediated…Nucresiran (ALN-TTRSC04)Alnylam PharmaceuticalsOngoing
Dec 13, 2024Phase 2,adaptive,double-blinded,placebo-controlled,randomized,multi-center trial to evaluate the efficacy,safety and tolerability of intracoronary infusion of…AB-1002Asklepios Biopharmaceutical, Inc.Ongoing
Oct 7, 2024A phase 2/3 multicenter, randomized, double-blind, placebo-controlled and open-label extension trial to evaluate the efficacy and safety of aficamten in a…Aficamten (CK-3773274)CytokineticsOngoing
Jul 11, 2024A follow-up, open-label, research evaluation of sustained treatment with aficamten (CK-3773274) in hypertrophic cardiomyopathy (HCM)Aficamten (CK-3773274)CytokineticsOngoing
May 27, 2024Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (attr cm)NNC6019-0001Novo NordiskOngoing
May 22, 2024A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic…Aficamten (CK-3773274)CytokineticsClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 25
Sep 30, 2026CamzyosTreatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve…MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb)Approved
Dec 19, 2025MyqorzoTreatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptomsCytokinetics Inc.Approved
Mar 20, 2025AmvuttraTreatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular…Alnylam Pharmaceuticals, Inc.Approved
Nov 22, 2024AttrubyTreatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular…BridgeBio Pharma, Inc.Approved
Apr 28, 2022CamzyosTreatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to…MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb)Approved
May 3, 2019Vyndaqel; VyndamaxVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis…FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.Approved
Apr 22, 2019CorlanorCorlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged…Amgen, Inc.,Approved
Jun 21, 2018AblysinolABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic…Belcher Pharmaceuticals, LLCApproved
May 26, 1995ZinecardCardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of…Pharmacia & UpjohnApproved
Jul 21, 2026S-Cibenzoline succinateTreatment of obstructive hypertrophic cardiomyopathy (oHCM)Celltrion, Inc.Designated
Jul 16, 2026A non-replication recombinant adeno-associated virus (AAV)…Treatment of dilated cardiomyopathy due to mutations in the BAG3 geneAffinia TherapeuticsDesignated
Jun 18, 2026NinerafaxstatTreatment of symptomatic nonobstructive hypertrophic cardiomyopathyImbria Pharmaceuticals, Inc.Designated
Nov 4, 2024IfetrobanTreatment of cardiomyopathy associated with Duchenne muscular dystrophyCumberland Pharmaceuticals Inc.Designated
Dec 14, 2023Adeno-associated virus serotype rh.10 encoding for the…Treatment of arrhythmogenic cardiomyopathy due to a PKP2 pathogenic variantLEXEO Therapeutics, Inc.Designated
Sep 21, 2023AtibuclimabTreatment of arrhythmogenic cardiomyopathyImplicit Bioscience Ltd.Designated

Medicines authorised in the EU

Newest first
Sep 18, 2026Tafamidis AccordTafamidis · genericAccord Healthcare S.L.U.EMA ↗
Feb 12, 2026MyqorzoAficamtenCytokinetics (Ireland) LimitedEMA ↗
Feb 10, 2025BeyonttraAcoramidisBayer AGEMA ↗
Jun 26, 2023CamzyosMavacamtenBristol-Myers Squibb Pharma EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.